Multimodal neuroimaging provides insights into the biology of Alzheimer's disease.

Abeliovich A, Schmitz Y, Farinas I, ChoiLundberg D, Ho WH, Castillo PE, et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000; 25: 239–52. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, et al. Mutations in progranulin cause taunegative frontotemporal dementia linked to chromosome 17. Nature 2006; 442: 916–19. Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006; 442: 920–4. Dickson DW, Kouri N, Murray ME, Josephs KA. Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J Mol Neurosci 2011; 45: 384–9. Forrest SL, Kril JJ, Stevens CH, Kwok JB, Hallupp M, Kim WS, et al. Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. Brain 2018; (In Press). doi: 10.1093/brain/awx328. Foster NL, Wilhelmsen K, Sima AA, Jones MZ, D’Amato CJ, Gilman S. Frontotem poral dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference Participants. Ann Neurol 1997; 41: 706–15. Kramer NJ, Carlomagno Y, Zhang YJ, Almeida S, Cook CN, Gendron TF, et al. Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science 2016; 353: 708–12. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 2010; 119: 1–4. Spillantini MG, Crowther RA, Goedert M. Comparison of the neurofibrillary pathology in Alzheimer’s disease and familial presenile dementia with tangles. Acta Neuropathol 1996; 92: 42–8. Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci USA 2009; 106: 18809–14.

[1]  K. Jellinger,et al.  Proteomics for synaptic markers of cognitive decline in neurodegenerative diseases. , 2018, Brain : a journal of neurology.

[2]  Clifford R. Jack,et al.  Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum , 2017, Cortex.

[3]  Gereon R Fink,et al.  NETWORKS OF TAU DISTRIBUTION IN ALZHEIMER’S DISEASE , 2017, Alzheimer's & Dementia.

[4]  Jorge Sepulcre,et al.  Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.

[5]  C. Jack,et al.  Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study , 2012, The Lancet Neurology.

[6]  G. Frisoni,et al.  Functional network disruption in the degenerative dementias , 2011, The Lancet Neurology.

[7]  R. Petersen,et al.  Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study , 2011, The Lancet Neurology.

[8]  Martin Beibel,et al.  Transmission and spreading of tauopathy in transgenic mouse brain , 2009, Nature Cell Biology.

[9]  K Patterson,et al.  Focal cortical presentations of Alzheimer's disease. , 2007, Brain : a journal of neurology.

[10]  Maurizio Corbetta,et al.  The human brain is intrinsically organized into dynamic, anticorrelated functional networks. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.